Your session is about to expire
← Back to Search
JNJ-64619178 for Cancer
Study Summary
This trial is testing a new cancer drug to see what doses are tolerated by patients with different types of cancer, including lymphoma and solid tumors. The goal is to also find out what doses of the drug might be effective in treating these cancers.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have at least one tumor that can be measured.I had a stem cell transplant from my own cells within the last 9 months or received a transplant from a donor.I haven't had cancer, except for certain skin cancers or cervical cancer in situ, in the last 3 years.I am fully active or restricted in physically strenuous activity but can do light work.I have B cell non-Hodgkin lymphoma, a solid tumor, or lower risk MDS.I have had a solid organ transplant.My cancer has spread to my brain or spinal cord.I am allergic to JNJ-64619178 or its ingredients.My organs are working well.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: Part 2:Dose Confirmation and Expansion
- Group 2: Part 1: Dose escalation and RP2D Selection
Frequently Asked Questions
What is the geographic breadth of this experiment?
"Presently, 6 medical centres are conducting this trial in Boston, Houston and Toronto as well as other nearby regions. To reduce travel obligations if you sign up for the study, it is advised that you select a clinic closest to your home."
Are there any enrollment opportunities for prospective participants in this research?
"Based on the information provided by clinicaltrials.gov, this particular trial is now closed to new participants. It was originally posted in July 2018 and last updated November 2022; however, at present there are still over 2,980 trials actively recruiting individuals."
Can you elucidate the extent of risk associated with JNJ-64619178?
"Given the Phase 1 stage of this trial, our team at Power judged JNJ-64619178 to be safe enough for use in clinical studies, giving it a score of 1."
Share this study with friends
Copy Link
Messenger